Odyssey Therapeutics

Odyssey Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of next-generation precision medicines for inflammatory diseases and cancer. Founded in 2021 and headquartered in Boston, Massachusetts, the company integrates advanced technologies in drug discovery, including high-throughput screening, structural biology, and artificial intelligence, to target complex biological pathways that were previously considered undruggable. Odyssey's platform aims to create a diverse pipeline of small molecules and protein therapeutics that address significant unmet medical needs. The company's strategy involves a multi-disciplinary approach, combining deep expertise in molecular biology with computational chemistry to accelerate the transition from target identification to clinical development. Their research focuses on modulating the immune system and targeting specific drivers of oncogenesis to provide more effective and safer treatments. Led by a team of experienced drug hunters and scientists, including founder and CEO Gary D. Glick, Odyssey Therapeutics has raised substantial capital to support its ambitious portfolio. By leveraging its integrated technology stack and specialized expertise, the company seeks to redefine the standards of care for patients suffering from life-threatening and chronic conditions through the delivery of highly potent and selective therapeutic candidates.